Roy Amariglio is an observer on GentiBio board of directors and Principal on the Israel team for OrbiMed Advisors LLC, a healthcare investment firm, covering venture capital investments in biotech, medical device, and diagnostics companies. Prior to joining OrbiMed, he was a Director of Mergers, Acquisitions, and Licensing at Bayer HealthCare where he was responsible for Healthcare transactions. While at Bayer, he held several positions of increasing responsibilities in Oncology Marketing and Business Development. Roy received his B.A. in Chemistry and Biology from Tel Aviv University and an M.Sc. and Ph.D. in Molecular Genetics from the Weizmann Institute in Israel, as well as an M.B.A. in Finance and Healthcare Management from the Wharton School of the University of Pennsylvania.
Roy Amariglio, PhD, MBA
Principal, OrbiMed, Board Observer